Enveric Biosciences stock drops amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 29 2024
0mins
Should l Buy ENVB?
Source: Benzinga
Enveric Biosciences Inc. experienced a significant decline of 32.62%, crossing below its 5-day SMA, reflecting the challenging market conditions.
This drop is attributed to broad market weakness, with the Nasdaq-100 down 0.59% and the S&P 500 slightly up by 0.06%. The overall market sentiment appears to be affecting investor confidence, leading to a sell-off in Enveric's stock despite its recent patent allowance news.
The implications of this decline suggest that while the company is making strides in its product pipeline, including the recent patent for its EVM301 Series aimed at treating mental health disorders, the broader market dynamics are currently overshadowing these positive developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENVB
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn its challenge against the company's new psilocybin patent, which targets mental health conditions such as depression, anxiety, and PTSD, thereby securing the company's intellectual property in the mental health sector.
- Positive Market Reaction: Following the withdrawal of the challenge, Enveric's stock rose over 4% in Wednesday's opening trade, reflecting investor optimism about the company's prospects, despite a year-to-date decline of 39% in its stock price.
- Potential Revenue: The related patents also cover treatments for depression and anxiety, with Enveric eligible to receive up to $205 million in total revenue from upfront, development, and sales milestone payments, enhancing the company's financial stability.
- Investor Sentiment Bullish: Retail sentiment on Stocktwits around Enveric is trending bullish, with extremely high message volumes indicating strong market interest, particularly after the withdrawal of Gilgamesh's challenge, which many investors consider “huge news.”
See More
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Gilgamesh Pharmaceuticals Inc. has withdrawn its Post-Grant Review petition against Enveric Biosciences' U.S. Patent No. 12,138,276, marking a significant victory for Enveric in protecting its intellectual property and ensuring its patent remains unchallenged.
- Legal Response Measures: Enveric hired Fish and Richardson P.C. in October 2025 to contest Gilgamesh's PGR petition and successfully filed a Request for Discretionary Denial, demonstrating the company's proactive stance in safeguarding its intellectual property.
- Importance of Patent Content: Enveric's '276 patent covers
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Enveric Biosciences Reveals New Data on EB-003
- Mechanistic Data Release: Enveric Biosciences shared new mechanistic data on its lead candidate EB-003, demonstrating its ability to activate both Gq and β-arrestin signaling pathways downstream of the 5-HT₂A receptor, providing crucial support for the development of this non-hallucinogenic neuroplastogen.
- Preclinical Research Findings: Multiple independent peer-reviewed studies have shown that selective activation of the 5-HT₂A receptor by either Gq-biased or β-arrestin-biased agonists can independently produce antidepressant and anxiolytic effects in preclinical models, further validating the potential efficacy of EB-003.
- Unique Signaling Mechanism: Enveric's proprietary bioluminescence resonance energy transfer (BRET) assays indicate that EB-003 exhibits a modest preference for β-arrestin over Gq signaling, potentially offering new insights into its safety and efficacy in clinical applications.
- Future Research Directions: CEO Joseph Tucker stated that Enveric plans to conduct further testing of EB-003's Gi signaling pathway to gain a comprehensive understanding of its unique signaling mechanisms, ensuring a well-understood biological basis before entering clinical trials to mitigate the risk of CNS drug failures.
See More
Enveric Biosciences Closes Direct Offering of Common Stock
- Funding Size: Enveric Biosciences successfully raised approximately $1.5 million by issuing 328,802 shares of common stock at $4.41 per share, with proceeds aimed at product development and working capital, enhancing the company's financial flexibility in the biotech sector.
- Warrant Issuance: The company concurrently issued series G and series H warrants, each allowing the purchase of 328,802 shares at an exercise price of $4.16 per share, with series G warrants expiring in five years and series H in eighteen months, thereby increasing investor engagement potential.
- Market Compliance: This offering was conducted under Nasdaq rules and an effective SEC registration statement, ensuring compliance and laying a foundation for future capital market activities, thus enhancing the company's credibility among investors.
- Strategic Development: With this financing, Enveric plans to accelerate the development of its neuroplastogenic small molecule therapies, particularly innovative drugs targeting psychiatric and neurological disorders, demonstrating the company's strategic commitment to addressing unmet medical needs.
See More
Enveric Biosciences Announces Direct Offering of Shares
- Offering Size: Enveric Biosciences is selling 328,802 shares at $4.41 each, expecting gross proceeds of approximately $1.5 million, which will be allocated for product development and working capital to enhance financial flexibility.
- Warrant Issuance: The company will issue Series G and Series H warrants, each exercisable for 328,802 shares at an exercise price of $4.16, with Series G warrants valid for five years and Series H for eighteen months, providing potential upside for investors.
- Market Reaction: Following the financing announcement, Enveric's shares fell over 12.5% in premarket trading, indicating market concerns regarding the offering and potentially impacting investor confidence.
- Transaction Timeline: The offering is expected to close on or about January 28, 2026, marking a further step in the company's capital market activities despite facing market volatility.
See More
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn its challenge against the company's new psilocybin patent, which targets mental health conditions such as depression, anxiety, and PTSD, thereby securing the company's intellectual property in the mental health sector.
- Positive Market Reaction: Following the withdrawal of the challenge, Enveric's stock rose over 4% in Wednesday's opening trade, reflecting investor optimism about the company's prospects, despite a year-to-date decline of 39% in its stock price.
- Potential Revenue: The related patents also cover treatments for depression and anxiety, with Enveric eligible to receive up to $205 million in total revenue from upfront, development, and sales milestone payments, enhancing the company's financial stability.
- Investor Sentiment Bullish: Retail sentiment on Stocktwits around Enveric is trending bullish, with extremely high message volumes indicating strong market interest, particularly after the withdrawal of Gilgamesh's challenge, which many investors consider “huge news.”
See More
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Gilgamesh Pharmaceuticals Inc. has withdrawn its Post-Grant Review petition against Enveric Biosciences' U.S. Patent No. 12,138,276, marking a significant victory for Enveric in protecting its intellectual property and ensuring its patent remains unchallenged.
- Legal Response Measures: Enveric hired Fish and Richardson P.C. in October 2025 to contest Gilgamesh's PGR petition and successfully filed a Request for Discretionary Denial, demonstrating the company's proactive stance in safeguarding its intellectual property.
- Importance of Patent Content: Enveric's '276 patent covers
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Enveric Biosciences Reveals New Data on EB-003
- Mechanistic Data Release: Enveric Biosciences shared new mechanistic data on its lead candidate EB-003, demonstrating its ability to activate both Gq and β-arrestin signaling pathways downstream of the 5-HT₂A receptor, providing crucial support for the development of this non-hallucinogenic neuroplastogen.
- Preclinical Research Findings: Multiple independent peer-reviewed studies have shown that selective activation of the 5-HT₂A receptor by either Gq-biased or β-arrestin-biased agonists can independently produce antidepressant and anxiolytic effects in preclinical models, further validating the potential efficacy of EB-003.
- Unique Signaling Mechanism: Enveric's proprietary bioluminescence resonance energy transfer (BRET) assays indicate that EB-003 exhibits a modest preference for β-arrestin over Gq signaling, potentially offering new insights into its safety and efficacy in clinical applications.
- Future Research Directions: CEO Joseph Tucker stated that Enveric plans to conduct further testing of EB-003's Gi signaling pathway to gain a comprehensive understanding of its unique signaling mechanisms, ensuring a well-understood biological basis before entering clinical trials to mitigate the risk of CNS drug failures.
See More
Enveric Biosciences Closes Direct Offering of Common Stock
- Funding Size: Enveric Biosciences successfully raised approximately $1.5 million by issuing 328,802 shares of common stock at $4.41 per share, with proceeds aimed at product development and working capital, enhancing the company's financial flexibility in the biotech sector.
- Warrant Issuance: The company concurrently issued series G and series H warrants, each allowing the purchase of 328,802 shares at an exercise price of $4.16 per share, with series G warrants expiring in five years and series H in eighteen months, thereby increasing investor engagement potential.
- Market Compliance: This offering was conducted under Nasdaq rules and an effective SEC registration statement, ensuring compliance and laying a foundation for future capital market activities, thus enhancing the company's credibility among investors.
- Strategic Development: With this financing, Enveric plans to accelerate the development of its neuroplastogenic small molecule therapies, particularly innovative drugs targeting psychiatric and neurological disorders, demonstrating the company's strategic commitment to addressing unmet medical needs.
See More
Enveric Biosciences Announces Direct Offering of Shares
- Offering Size: Enveric Biosciences is selling 328,802 shares at $4.41 each, expecting gross proceeds of approximately $1.5 million, which will be allocated for product development and working capital to enhance financial flexibility.
- Warrant Issuance: The company will issue Series G and Series H warrants, each exercisable for 328,802 shares at an exercise price of $4.16, with Series G warrants valid for five years and Series H for eighteen months, providing potential upside for investors.
- Market Reaction: Following the financing announcement, Enveric's shares fell over 12.5% in premarket trading, indicating market concerns regarding the offering and potentially impacting investor confidence.
- Transaction Timeline: The offering is expected to close on or about January 28, 2026, marking a further step in the company's capital market activities despite facing market volatility.
See More
